Pathways to Drug Development for Autism Spectrum Disorders
The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
Autism spectrum disorders (ASDs) are neurodevelopmental disorders whose prevalence has risen over the past two decades. Current drug treatments for ASDs and the related disorders--fragile X syndrome (FXS) and Rett syndrome--target specific symptoms but do not address the basic underlying etiologies. However, based partly on an improved understanding of the neurochemical underpinnings of FXS, pharmacotherapy for this syndrome has progressed to the point of clinical trials of several novel drug treatments. By contrast, our overall understanding of the neuropathophysiology of ASDs is still rudimentary. There is hope in the field that knowledge and experience gained in the study of fragile X and Rett syndromes may be applicable to the larger autism patient population. In this review, we discuss how recent advances in our understanding of the biochemistry and neuropathology of these disorders could lead to new more effective treatments for ASDs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuroglial activation and neuroinflammation in the brain of patients with autism
Vargas, D. L., Nascimbene, C., Krishnan, C., Zimmerman, A. W., & Pardo, C. A. (2005) · Annals of Neurology · doi:10.1002/ana.20315 · Cited by 2,149 · cited 1×
“50 and plasma and brain tissue from patients with ASDs”
BackgroundFMRP Stalls Ribosomal Translocation on mRNAs Linked to Synaptic Function and Autism
Darnell, J. C., Van Driesche, S. J., Zhang, C., Hung, K. Y. S., Mele, A., Fraser, C. E., Stone, E. F., Chen, C., Fak, J. J., Chi, S. W., et al. (2011) · Cell · doi:10.1016/j.cell.2011.06.013 · Cited by 2,072 · cited 1×
“FMRP is an mRNA binding protein that regulates the translation of about 4% of brain mRNAs”
BackgroundFunctional impact of global rare copy number variation in autism spectrum disorders
Pinto, D., Pagnamenta, A. T., Klei, L., Anney, R., Merico, D., Regan, R., Conroy, J., Magalhaes, T. R., Correia, C., Abrahams, B. S., et al. (2010) · Nature · doi:10.1038/nature09146 · Cited by 2,013
Transcriptomic Analysis of Autistic Brain Reveals Convergent Molecular Pathology
Voineagu, I., Wang, X., Johnston, P., Lowe, J. K., Tian, Y., Horvath, S., Mill, J., Cantor, R. M., Blencowe, B. J., & Geschwind, D. H. (2011) · Nature · doi:10.1038/nature10110 · Cited by 1,874
The mGluR theory of fragile X mental retardation
Bear, M. F., Huber, K. M., & Warren, S. T. (2004) · Trends in Neurosciences · doi:10.1016/j.tins.2004.04.009 · Cited by 1,580
Dendritic spine pathology in neuropsychiatric disorders
Penzes, P., Cahill, M. E., Jones, K. A., VanLeeuwen, J.-E., & Woolfrey, K. M. (2011) · Nature Neuroscience · doi:10.1038/nn.2741 · Cited by 1,523
Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes
Foust, K. D., Nurre, E., Montgomery, C. L., Hernandez, A., Chan, C. M., & Kaspar, B. K. (2009) · Nature Biotechnology · doi:10.1038/nbt.1515 · Cited by 1,456 · cited 1×
“A major step toward the goal of systemic gene delivery to the CNS using AAV has been taken by Foust and colleagues”
BackgroundReversal of Neurological Defects in a Mouse Model of Rett Syndrome
Guy, J., Gan, J., Selfridge, J., Cobb, S., & Bird, A. (2007) · Science · doi:10.1126/science.1138389 · Cited by 1,230
Dysfunction in GABA signalling mediates autism-like stereotypies and Rett syndrome phenotypes
Chao, H.-T., Chen, H., Samaco, R. C., Xue, M., Chahrour, M., Yoo, J., Neul, J. L., Gong, S., Lu, H.-C., Heintz, N., et al. (2010) · Nature · doi:10.1038/nature09582 · Cited by 1,168
Morgan, J. T., Chana, G., Pardo, C. A., Achim, C., Semendeferi, K., Buckwalter, J., Courchesne, E., & Everall, I. P. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.05.024 · Cited by 749
Rare de novo and transmitted copy-number variation in autistic spectrum disorders
Levy, D., Ronemus, M., Yamrom, B., Lee, Y.-H., Leotta, A., Kendall, J., Marks, S., Lakshmi, B., Pai, D., Ye, K., et al. (2011) · Neuron · doi:10.1016/j.neuron.2011.05.015 · Cited by 712
Autism spectrum disorders and autistic traits: A decade of new twin studies
Ronald, A., & Hoekstra, R. A. (2011) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.31159 · Cited by 616
Jacquemont, S., Curie, A., des Portes, V., Torrioli, M. G., Berry-Kravis, E., Hagerman, R. J., Ramos, F. J., Cornish, K., He, Y., Paulding, C., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001708 · Cited by 609
Graeber, M. B. (2010) · Science · doi:10.1126/science.1190929 · Cited by 608
Partial reversal of Rett Syndrome-like symptoms in MeCP2 mutant mice
Tropea, D., Giacometti, E., Wilson, N. R., Beard, C., McCurry, C., Fu, D. D., Flannery, R., Jaenisch, R., & Sur, M. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0812394106 · Cited by 593 · cited 1×
“Treatment with IGF-1 has been shown to alleviate immature synapses and rescue several phenotypes in a mouse model of Rett syndrome”
BackgroundAutism spectrum disorders-a genetics review
Miles, J. H. (2011) · Genetics in Medicine · doi:10.1097/gim.0b013e3181ff67ba · Cited by 567
Dysregulation of mTOR signaling in fragile X syndrome
Sharma, A., Hoeffer, C. A., Takayasu, Y., Miyawaki, T., McBride, S. M., Klann, E., & Zukin, R. S. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.3696-09.2010 · Cited by 557
Immune proteins in brain development and synaptic plasticity
Boulanger, L. M. (2009) · Neuron · doi:10.1016/j.neuron.2009.09.001 · Cited by 555 · cited 1×
“Unimpeded interactions between these systems could promote autoimmunity, impair the body's capacity to fight infections, or cause intellectual deterioration”
BackgroundMaternal infection and immune involvement in autism
Patterson, P. H. (2011) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2011.03.001 · Cited by 520
Mitochondrial dysfunction in autism
Giulivi, C., Zhang, Y.-F., Omanska-Klusek, A., Ross-Inta, C., Wong, S., Hertz-Picciotto, I., Tassone, F., & Pessah, I. N. (2010) · JAMA · doi:10.1001/jama.2010.1706 · Cited by 466
Evidence for a cerebellar role in reduced exploration and stereotyped behavior in autism
Pierce, K., & Courchesne, E. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(00)01008-8 · Cited by 464 · cited 1×
“Decreased volume of the cerebellar vermis has also been consistently reported in individuals with ASD, and repetitive and exploratory behaviors have been shown to correlate with vermis size in children with ASDs, but not in controls”
BackgroundGABAA Receptor Downregulation in Brains of Subjects with Autism
Fatemi, S. H., Reutiman, T. J., Folsom, T. D., & Thuras, P. D. (2009) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-008-0646-7 · Cited by 439
Association of Family History of Autoimmune Diseases and Autism Spectrum Disorders
Atladóttir, H. O., Pedersen, M. G., Thorsen, P., Mortensen, P. B., Deleuran, B., Eaton, W. W., & Parner, E. T. (2009) · Pediatrics · doi:10.1542/peds.2008-2445 · Cited by 404 · cited 1×
“Genes Linked To ASDs Twin and family studies have firmly established that ASDs are highly heritable”
BackgroundBrainstem, cerebellar and limbic neuroanatomical abnormalities in autism
Courchesne, E. (1997) · Current Opinion in Neurobiology · doi:10.1016/s0959-4388(97)80016-5 · Cited by 401
Osterweil, E. K., Krueger, D. D., Reinhold, K., & Bear, M. F. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.3888-10.2010 · Cited by 384
Immune transcriptome alterations in the temporal cortex of subjects with autism
Garbett, K., Ebert, P. J., Mitchell, A., Lintas, C., Manzi, B., Mirnics, K., & Persico, A. M. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.01.012 · Cited by 375
Wei, H., Zou, H., Sheikh, A. M., Malik, M., Dobkin, C., Brown, W. T., & Li, X. (2011) · Journal of Neuroinflammation · doi:10.1186/1742-2094-8-52 · Cited by 333
Review of neuroimaging in autism spectrum disorders: what have we learned and where we go from here
Anagnostou, E., & Taylor, M. J. (2011) · Molecular Autism · doi:10.1186/2040-2392-2-4 · Cited by 321
Durand, C. M., Perroy, J., Loll, F., Perrais, D., Fagni, L., Bourgeron, T., Montcouquiol, M., & Sans, N. (2012) · Molecular Psychiatry · doi:10.1038/mp.2011.57 · Cited by 316
FMRP Mediates mGluR5-Dependent Translation of Amyloid Precursor Protein
Westmark, C. J., & Malter, J. S. (2007) · PLoS Biology · doi:10.1371/journal.pbio.0050052 · Cited by 296 · cited 1×
“47 A link between FXS and APP/Aβ was discovered when it was shown that FMRP binds to and regulates the translation of APP mRNA”
BackgroundFragile X and autism: intertwined at the molecular level leading to targeted treatments
Hagerman, R., Hoem, G., & Hagerman, P. (2010) · Molecular Autism · doi:10.1186/2040-2392-1-12 · Cited by 247
Harada, M., Taki, M. M., Nose, A., Kubo, H., Mori, K., Nishitani, H., & Matsuda, T. (2011) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-010-1065-0 · Cited by 231
Open-label add-on treatment trial of minocycline in fragile X syndrome.
Paribello, C., Tao, L., Folino, A., Berry-Kravis, E., Tranfaglia, M., Ethell, I. M., & Ethell, D. W. (2010) · BMC Neurology · doi:10.1186/1471-2377-10-91 · Cited by 223 · cited 1×
“Promising results from preclinical research and a small clinical trial of the immune-suppressing drug minocycline in FXS provide evidence in favor of this idea”
ResultReduced AKT/mTOR signaling and protein synthesis dysregulation in a Rett syndrome animal model
Ricciardi, S., Boggio, E. M., Grosso, S., Lonetti, G., Forlani, G., Stefanelli, G., Calcagno, E., Morello, N., Landsberger, N., Biffo, S., et al. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddq563 · Cited by 223
Decreased GABA B receptors in the cingulate cortex and fusiform gyrus in Autism
Oblak, A. L., Gibbs, T. T., & Blatt, G. J. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06858.x · Cited by 203
Connecting Genes to Brain in the Autism Spectrum Disorders
Abrahams, B. S., & Geschwind, D. H. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.47 · Cited by 193 · cited 1×
“It is worth noting that variants in these genes have been observed not only in individuals with an ASD diagnosis but also in patients with related conditions such as nonsyndromic mental retardation”
BackgroundAstrocytes prevent abnormal neuronal development in the fragile X mouse.
Jacobs, S., & Doering, L. C. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.5027-09.2010 · Cited by 170
Autism, Alzheimer disease, and fragile X
Sokol, D. K., Maloney, B., Long, J. M., Ray, B., & Lahiri, D. K. (2011) · Neurology · doi:10.1212/wnl.0b013e3182166dc7 · Cited by 141
Parker-Athill, E. C., & Tan, J. (2010) · Neurosignals · doi:10.1159/000319828 · Cited by 140
Pacey, L. K. K., Heximer, S. P., & Hampson, D. R. (2009) · Molecular Pharmacology · doi:10.1124/mol.109.056127 · Cited by 133 · cited 1×
“29 and R-baclofen rescues audiogenic seizures in Fmr1 mice”
BackgroundSelf-citationTuberous sclerosis: A primary pathology of astrocytes?
Sosunov, A. A., Wu, X., Weiner, H. L., Mikell, C. B., Goodman, R. R., Crino, P. D., & McKhann, G. M. (2008) · Epilepsia · doi:10.1111/j.1528-1167.2008.01493.x · Cited by 106
Greco, C. M., Navarro, C. S., Hunsaker, M. R., Maezawa, I., Shuler, J. F., Tassone, F., Delany, M., Au, J. W., Berman, R. F., Jin, L.-W., et al. (2011) · Molecular Autism · doi:10.1186/2040-2392-2-2 · Cited by 90
Martin, L. A., Goldowitz, D., & Mittleman, G. (2010) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2009.07073.x · Cited by 82
Plasma cytokine profiles in Fragile X subjects: Is there a role for cytokines in the pathogenesis?
Ashwood, P., Nguyen, D. V., Hessl, D., Hagerman, R. J., & Tassone, F. (2010) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2010.01.008 · Cited by 80 · cited 1×
“Immune activation is demonstrated in part by reports describing elevated cytokines and chemokines in blood plasma from patients with FX”
BackgroundYuskaitis, C. J., Beurel, E., & Jope, R. S. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2010.06.015 · Cited by 79
Loss of the tuberous sclerosis complex protein tuberin causes Purkinje cell degeneration
Reith, R. M., Way, S., McKenna, J., Haines, K., & Gambello, M. J. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.02.014 · Cited by 65
The neurochemical basis for the treatment of autism spectrum disorders and Fragile X syndrome
Hampson, D. R., Adusei, D. C., & Pacey, L. K. K. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.02.005 · Cited by 34
Self-citation
Cited by
Lionel, A. C., Tammimies, K., Vaags, A. K., Rosenfeld, J. A., Ahn, J. W., Merico, D., Noor, A., Runke, C. K., Pillalamarri, V. K., Carter, M. T., et al. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddt669 · Cited by 163
Bachmann, C. J., Manthey, T., Kamp-Becker, I., Glaeske, G., & Hoffmann, F. (2013) · Research in Developmental Disabilities · doi:10.1016/j.ridd.2013.05.028 · Cited by 63
Gholizadeh, S., Tharmalingam, S., MacAldaz, M. E., & Hampson, D. R. (2013) · Human Gene Therapy Methods · doi:10.1089/hgtb.2013.076 · Cited by 61
Persistent astrocyte activation in the fragile X mouse cerebellum
Pacey, L. K. K., Guan, S., Tharmalingam, S., Thomsen, C., & Hampson, D. R. (2015) · Brain and Behavior · doi:10.1002/brb3.400 · Cited by 39
Self-citationPharmacogenomic Medicine in Autism: Challenges and Opportunities
Bowers, K., Lin, P.-I., & Erickson, C. (2015) · Pediatric Drugs · doi:10.1007/s40272-014-0106-0 · Cited by 22
Metadata
- Authors
- Hampson, D. R., Gholizadeh, S., & Pacey, L. K. K.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2011-12-28
- Volume
- 91
- Issue
- 2
- Pages
- 189-200
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W2021997289
- Cited by
- 53
- References
- 47
- FWCI
- 5.30
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.